V. E. Vinogradov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. E. Vinogradov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ilya Victorovich Dmitriev
N.V. Sklifosovsky Research Institute for Emergency Medicine; N.I. Pirogov Russian National Research Medical University
3 shared publications - Oleg N. Kotenko
Pirogov Russian National Research Medical University; Moscow Clinical Research Center Hospital No. 52 of the Moscow Department of Health
3 shared publications - Aslan G. Balkarov
N.V. Sklifosovsky Research Institute for Emergency Medicine ; N.I. Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications - L. Yu. Artyukhina
Municipal Clinical Hospital No. 52
2 shared publications - Nadiya F. Frolova
Moscow Clinical Research Center «Hospital No. 52»; Russian University of Medicine of the Ministry of Health of the Russian Federation
2 shared publications - Nonna V. Shmarina
N.V. Sklifosovsky Research Institute for Emergency Medicine; N.I. Pirogov Russian National Research Medical University (Pirogov University)
2 shared publications
Latest Publications
- Open Access
- 10 January 2026
- Published by V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs in Russian Journal of Transplantology and Artificial Organs
- Vol. 27 (4) , 31-40
Effect of pre-transplant dialysis modality on outcomes in the first two years after kidney transplantation
Kidney transplantation (KT) is the treatment of choice for patients with end-stage renal disease (ESRD), off ering superior survival and quality of life compared with dialysis. Several observational studies have investigated the infl uence of hemodialysis (HD) and peritoneal dialysis (PD) on post-transplant outcomes. Objective: to assess the effect of dialysis modality prior to KT on outcomes during the fi rst two years after transplantation. Materials and methods . The study included 95 KT recipients, divided into two groups: (1) patients previously treated with PD (n = 45) and (2) patients previously treated with HD (n = 50). The groups were comparable in age, dialysis duration, and immunosuppressive therapy regimens. The mean follow-up period was 19.4 ± 6.4 months. Results . Delayed graft function (DGF) occurred less frequently in the PD group (17.8%) compared with the HD group (34%), although the diff erence did not reach statistical signifi cance (p = 0.08). Patients in the HD group required signifi cantly more rehospitalizations, with a median of 2.24 [1–3] compared to 1.9 [0–2.5] in the PD group (p = 0.01). Infectious complications were also more common among HD patients (62% vs 42%, p = 0.005). In particular, bacterial infections occurred signifi cantly more often in the HD group (63% vs 43%, p = 0.0001), whereas viral and fungal infections were detected at similar frequencies in both groups (p > 0.2). The incidence of graft rejection was comparable between groups. Two-year graft survival (91% in PD vs 94% in HD, p = 0.8) and patient survival (94% in PD vs 96% in HD, p = 0.9) did not diff er signifi cantly. Likewise, serum creatinine and daily proteinuria at the end of follow-up showed no statistically signifi cant diff erences (p = 0.7 and p = 0.3, respectively). Conclusion . In this study, patients who received PD prior to transplantation showed more favorable post-transplant outcomes, including a signifi cantly lower frequency of rehospitalizations and infectious complications, as well as a trend toward reduced DGF. However, two-year graft and patient survival were similar between the PD and HD groups.
- 10 January 2026
- Published by V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs in Russian Journal of Transplantology and Artificial Organs
- Vol. 27 (4) , 31-40
Open AccessEffect of pre-transplant dialysis modality on outcomes in the first two years after kidney transplantation
Kidney transplantation (KT) is the treatment of choice for patients with end-stage renal disease (ESRD), off ering superior survival and quality of life compared with dialysis. Several observational studies have investigated the infl uence of hemodialysis (HD) and peritoneal dialysis (PD) on post-transplant outcomes. Objective: to assess the effect of dialysis modality prior to KT on outcomes during the fi rst two years after transplantation. Materials and methods . The study included 95 KT recipients, divided into two groups: (1) patients previously treated with PD (n = 45) and (2) patients previously treated with HD (n = 50). The groups were comparable in age, dialysis duration, and immunosuppressive therapy regimens. The mean follow-up period was 19.4 ± 6.4 months. Results . Delayed graft function (DGF) occurred less frequently in the PD group (17.8%) compared with the HD group (34%), although the diff erence did not reach statistical signifi cance (p = 0.08). Patients in the HD group required signifi cantly more rehospitalizations, with a median of 2.24 [1–3] compared to 1.9 [0–2.5] in the PD group (p = 0.01). Infectious complications were also more common among HD patients (62% vs 42%, p = 0.005). In particular, bacterial infections occurred signifi cantly more often in the HD group (63% vs 43%, p = 0.0001), whereas viral and fungal infections were detected at similar frequencies in both groups (p > 0.2). The incidence of graft rejection was comparable between groups. Two-year graft survival (91% in PD vs 94% in HD, p = 0.8) and patient survival (94% in PD vs 96% in HD, p = 0.9) did not diff er signifi cantly. Likewise, serum creatinine and daily proteinuria at the end of follow-up showed no statistically signifi cant diff erences (p = 0.7 and p = 0.3, respectively). Conclusion . In this study, patients who received PD prior to transplantation showed more favorable post-transplant outcomes, including a signifi cantly lower frequency of rehospitalizations and infectious complications, as well as a trend toward reduced DGF. However, two-year graft and patient survival were similar between the PD and HD groups.
- 26 December 2025
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 27 (4)
Clinical evidence and outcomes of atypical hemolytic uremic syndrome in terms of genetic complement abnormalities
The aim of this retrospective study was to comparatively analyze the clinical course and outcomes of aHUS with genetic complement abnormalities using both our own data and published literature. Materials and methods . This retrospective study included 55 patients with aHUS (mean age 36.4±8.9 years, 56% male, 44% female) treated between January 2014 and August 2024 at the Moscow Scientific and Practical Center of Nephrology and Pathology of Transplanted Kidney of Moscow City Hospital No 52. Results . Genetic abnormalities were identified in 61% of patients with aHUS. The most frequently detected variants were CFHR3/CFHR1 (29%), C3 (20%) and CFH (15%). Patients with and without genetic mutations did not differ significantly in sex, age, presence of the full TMA triad, malignant arterial hypertension (MAH), or extrarenal manifestations (р>0.05). Cardiac involvement was more common in patients with CFH variants (24%), and intestinal involvement was more frequent in patients with CFHR3/CFHR1 (56%); however these differences did not reach statistical significance ( р >0.05). Five-year renal survival did not differ significantly between patients with or without genetic mutations (50% vs. 65%, respectively, р =0.413), or depending on the presence of MAH (38% vs. 64%, р =0.08) or extrarenal manifestations (43% vs. 64%, р =0.17). All patients with CFH mutation experienced loss of renal function within 5 years despite treatment with eculizumab. A significant improvement in renal survival was observed only in patients who initiated eculizumab therapy within first month of disease onset, compared with those who started treatment after a month or later (89% vs. 11%, respectively, р =0.0001). The five-year mortality rate among patients with aHUS was 7%. Mortality did not differ significantly based on the presence of genetic abnormalities (0% vs. 16%, р =0.295), MAH (33% and 6%, р >0.5) or extrarenal manifestations (14% vs. 0%, р =0.451). Conclusions . Demographic and clinical characteristics did not differ significantly between patients with or without complement-related genetic abnormalities. A pronounced decrease in renal survival was observed found in patients with CFH mutations compared with whose carrying CFHR1/CFHR3 or without genetic mutations. Five-year renal survival and mortality rate were not significantly associated with other genetic variants, MAH, or extrarenal involvement. Early initiation of eculizumab therapy – within the first month after disease onset – markedly improved renal outcomes and reduces mortality.
- 26 December 2025
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 27 (4)
Clinical evidence and outcomes of atypical hemolytic uremic syndrome in terms of genetic complement abnormalities
The aim of this retrospective study was to comparatively analyze the clinical course and outcomes of aHUS with genetic complement abnormalities using both our own data and published literature. Materials and methods . This retrospective study included 55 patients with aHUS (mean age 36.4±8.9 years, 56% male, 44% female) treated between January 2014 and August 2024 at the Moscow Scientific and Practical Center of Nephrology and Pathology of Transplanted Kidney of Moscow City Hospital No 52. Results . Genetic abnormalities were identified in 61% of patients with aHUS. The most frequently detected variants were CFHR3/CFHR1 (29%), C3 (20%) and CFH (15%). Patients with and without genetic mutations did not differ significantly in sex, age, presence of the full TMA triad, malignant arterial hypertension (MAH), or extrarenal manifestations (р>0.05). Cardiac involvement was more common in patients with CFH variants (24%), and intestinal involvement was more frequent in patients with CFHR3/CFHR1 (56%); however these differences did not reach statistical significance ( р >0.05). Five-year renal survival did not differ significantly between patients with or without genetic mutations (50% vs. 65%, respectively, р =0.413), or depending on the presence of MAH (38% vs. 64%, р =0.08) or extrarenal manifestations (43% vs. 64%, р =0.17). All patients with CFH mutation experienced loss of renal function within 5 years despite treatment with eculizumab. A significant improvement in renal survival was observed only in patients who initiated eculizumab therapy within first month of disease onset, compared with those who started treatment after a month or later (89% vs. 11%, respectively, р =0.0001). The five-year mortality rate among patients with aHUS was 7%. Mortality did not differ significantly based on the presence of genetic abnormalities (0% vs. 16%, р =0.295), MAH (33% and 6%, р >0.5) or extrarenal manifestations (14% vs. 0%, р =0.451). Conclusions . Demographic and clinical characteristics did not differ significantly between patients with or without complement-related genetic abnormalities. A pronounced decrease in renal survival was observed found in patients with CFH mutations compared with whose carrying CFHR1/CFHR3 or without genetic mutations. Five-year renal survival and mortality rate were not significantly associated with other genetic variants, MAH, or extrarenal involvement. Early initiation of eculizumab therapy – within the first month after disease onset – markedly improved renal outcomes and reduces mortality.
- Open Access
- 8 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6123
Cardiovascular involvement in patients with Fabry disease
Aim. Retrospective analysis of cardiovascular involvement in a patient with Fabry disease.Material and methods. This retrospective assessment included 34 cases of Fabry disease (men, 64,7%). The median age of Fabry patients was 43,5 (32,8; 57) years.Results. Cardiac involvement was detected in 70,6% of patients. Acute cerebro-vascular events were noted in 23,5% of patients aged 32,5 (25,3; 51,5) years. Kidney damage was detected in 82,4% of patients, while hemodialysis was performed in 14,7% of patients. Among 24 patients with Fabry disease with cardiac damage, heart failure was diagnosed in 37,5% of patients. Simpson’s left ventricular (LV) ejection fraction (EF) was 60 (52,6; 66,7)%. LVEF >50% was detected in 83,3% of patients, LVEF of 40-50% — in 16,7% of patients. LV wall thickening was noted in 83,3% of patients, of which 58,3% had LV wall thickness ≥1,5 cm. Small pericardial effusion was detected in 12,5% of patients. LV diastolic dysfunction was detected in 45,8% of patients. Sinus bradycardia was detected in 41,7% of patients. Short PQ interval was detected in 25% of patients, while Wolff-Parkinson-White syndrome was detected in 8,3%.Conclusion. Cardiac involvement with wall thickening, sinus bradycardia and atrioventricular conduction disorders are frequent manifestations in patients with Fabry disease. Early detection of cardiac involvement and prevention of cardiac events are important to ensure the effectiveness of treatment and improve the quality of life of patients.
- 8 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6123
Open AccessCardiovascular involvement in patients with Fabry disease
Aim. Retrospective analysis of cardiovascular involvement in a patient with Fabry disease.Material and methods. This retrospective assessment included 34 cases of Fabry disease (men, 64,7%). The median age of Fabry patients was 43,5 (32,8; 57) years.Results. Cardiac involvement was detected in 70,6% of patients. Acute cerebro-vascular events were noted in 23,5% of patients aged 32,5 (25,3; 51,5) years. Kidney damage was detected in 82,4% of patients, while hemodialysis was performed in 14,7% of patients. Among 24 patients with Fabry disease with cardiac damage, heart failure was diagnosed in 37,5% of patients. Simpson’s left ventricular (LV) ejection fraction (EF) was 60 (52,6; 66,7)%. LVEF >50% was detected in 83,3% of patients, LVEF of 40-50% — in 16,7% of patients. LV wall thickening was noted in 83,3% of patients, of which 58,3% had LV wall thickness ≥1,5 cm. Small pericardial effusion was detected in 12,5% of patients. LV diastolic dysfunction was detected in 45,8% of patients. Sinus bradycardia was detected in 41,7% of patients. Short PQ interval was detected in 25% of patients, while Wolff-Parkinson-White syndrome was detected in 8,3%.Conclusion. Cardiac involvement with wall thickening, sinus bradycardia and atrioventricular conduction disorders are frequent manifestations in patients with Fabry disease. Early detection of cardiac involvement and prevention of cardiac events are important to ensure the effectiveness of treatment and improve the quality of life of patients.
- Open Access
- 13 February 2023
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 13 (2) , 112-116
Acute cell rejection of a kidney transplant in a patient of african origin: clinical observation
The origin of the recipient is one of the recipient-related factors that statistically significantly affects the outcomes of kidney transplantation, but this factor is not so relevant in our country. The article presents the first experience of kidney transplantation in a patient of African descent at the N.I. N.V. Sklifosovsky.Material and methods. Allogeneic renal graft transplantation from a post-mortem donor was performed in a 60-year-old African male patient with stage 5 chronic kidney disease as a result of hypertensive nephroangiosclerosis.Results. The early postoperative period was complicated by the development of acute cellular graft rejection grade 1a-b according to Banff. Anti-crisis therapy was performed with some positive effect, however, in the late postoperative period, a loss of renal graft function was noted, and the patient was returned to renal replacement therapy with program hemodialysis.Conclusion. Patients of African ancestry are at increased risk of adverse outcomes due to immunological causes and require more careful immunological selection of a donor organ, an enhanced immunosuppressive regimen, and close monitoring after transplantation.
- 13 February 2023
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 13 (2) , 112-116
Open AccessAcute cell rejection of a kidney transplant in a patient of african origin: clinical observation
The origin of the recipient is one of the recipient-related factors that statistically significantly affects the outcomes of kidney transplantation, but this factor is not so relevant in our country. The article presents the first experience of kidney transplantation in a patient of African descent at the N.I. N.V. Sklifosovsky.Material and methods. Allogeneic renal graft transplantation from a post-mortem donor was performed in a 60-year-old African male patient with stage 5 chronic kidney disease as a result of hypertensive nephroangiosclerosis.Results. The early postoperative period was complicated by the development of acute cellular graft rejection grade 1a-b according to Banff. Anti-crisis therapy was performed with some positive effect, however, in the late postoperative period, a loss of renal graft function was noted, and the patient was returned to renal replacement therapy with program hemodialysis.Conclusion. Patients of African ancestry are at increased risk of adverse outcomes due to immunological causes and require more careful immunological selection of a donor organ, an enhanced immunosuppressive regimen, and close monitoring after transplantation.
- Open Access
- 21 June 2021
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 13 (2) , 130-140
Patient and kidney graft survival rates after first and second kidney transplantation
Introduction. Expanding donation criteria is one way of solving the problem of the increasing need of transplantation. The article is dedicated to comparison of the outcomes of first and second repeated kidney transplantation using grafts from standard criteria and expanded criteria donors.Aim. To evaluate 1-year and 5-year recipient and kidney graft survival rates after first and second kidney transplantation according to the donor type – standard criteria or expanded criteria donors.Material and methods. From 2007 till 2019 we performed 1459 kidney transplantations. The comparison study of outcomes of first (n=196) and second (n=143) kidney transplantations from standard criteria (n=245) and expanded criteria (n=94) donors was made.Results. There were no significant differences in a 1-year patient survival according to the donor type (98% and 95%, p=0.13). A 5-year recipient survival was significantly poorer after kidney transplantation from expanded criteria donors (97.6% and 88%, p=0.01). There were no significant differences in 1-year and 5-year graft survival rates according to the order of transplantation (p=0.21 and p=0.36). We found no significant difference in 1-year recipient survival after kidney transplantation from expanded criteria donors according to the order of transplantation (p=0.50). A 5-year recipient survival was significantly difference poorer after second kidney transplantation from expanded criteria donors (p=0.04). One-year and 5-year graft survival rates were significantly lower after kidney transplantation from expanded criteria donors (94%, 88% vs 86%, 65%, p=0.0025 and p=0.0011, respectively). One-year and 5-year survival rates were higher after first kidney transplantation from standard criteria donors in comparison with second kidney transplantation (p=0.052 and p=0.02, statistically significant in both cases). Analyzing outcomes of kidney transplantation from expanded criteria donors we found 1-year and 5-year graft survivals to be higher after first kidney transplantation comparing with second kidney transplantation (p=0.030 and p=0.018, statistically significant in both cases).Conclusion. In case of second organ transplantation, it is reasonable to use organs from standard criteria donors.
- 21 June 2021
- Published by IPO Association of Transplantologists in Transplantologiya. The Russian Journal of Transplantation
- Vol. 13 (2) , 130-140
Open AccessPatient and kidney graft survival rates after first and second kidney transplantation
Introduction. Expanding donation criteria is one way of solving the problem of the increasing need of transplantation. The article is dedicated to comparison of the outcomes of first and second repeated kidney transplantation using grafts from standard criteria and expanded criteria donors.Aim. To evaluate 1-year and 5-year recipient and kidney graft survival rates after first and second kidney transplantation according to the donor type – standard criteria or expanded criteria donors.Material and methods. From 2007 till 2019 we performed 1459 kidney transplantations. The comparison study of outcomes of first (n=196) and second (n=143) kidney transplantations from standard criteria (n=245) and expanded criteria (n=94) donors was made.Results. There were no significant differences in a 1-year patient survival according to the donor type (98% and 95%, p=0.13). A 5-year recipient survival was significantly poorer after kidney transplantation from expanded criteria donors (97.6% and 88%, p=0.01). There were no significant differences in 1-year and 5-year graft survival rates according to the order of transplantation (p=0.21 and p=0.36). We found no significant difference in 1-year recipient survival after kidney transplantation from expanded criteria donors according to the order of transplantation (p=0.50). A 5-year recipient survival was significantly difference poorer after second kidney transplantation from expanded criteria donors (p=0.04). One-year and 5-year graft survival rates were significantly lower after kidney transplantation from expanded criteria donors (94%, 88% vs 86%, 65%, p=0.0025 and p=0.0011, respectively). One-year and 5-year survival rates were higher after first kidney transplantation from standard criteria donors in comparison with second kidney transplantation (p=0.052 and p=0.02, statistically significant in both cases). Analyzing outcomes of kidney transplantation from expanded criteria donors we found 1-year and 5-year graft survivals to be higher after first kidney transplantation comparing with second kidney transplantation (p=0.030 and p=0.018, statistically significant in both cases).Conclusion. In case of second organ transplantation, it is reasonable to use organs from standard criteria donors.